Articles tagged with Cancer Cells
Researchers propose that quantum metabolism explains metabolic changes causing healthy cells to become cancerous, enabling cells to outcompete for space and nutrients. Understanding this process could lead to new cancer treatment approaches.
Researchers developed a new pulsed photoacoustic technique to detect a small number of cancer cells in vitro. The technique combines high optical contrast with high resolution, allowing for the detection of single cancer cells.
Researchers at Queen Mary University of London have identified a mechanism by which normal cells can become cancerous. By understanding how the FOXM1 gene influences cell behavior, scientists may be able to develop new diagnostic tests to detect cancer at an early stage.
Researchers have discovered that a specific protein called p21 can kill certain cancer cells, including sarcomas, by sensitizing their mitochondria to oxidants. This finding provides a rationale for testing existing drugs that increase p21 levels in these types of cancers.
Researchers aim to create targeted compounds that selectively attack cancerous cells by zeroing-in on pollutants produced by tumors' characteristic metabolism. This approach seeks to minimize side effects associated with conventional chemotherapy.
Researchers discovered a two-step ritual in which RNA telomerase partners are prepared for interaction, revealing novel pharmaceutical approaches to cancer and diseases of aging. The study sheds light on the complex process of telomerase biogenesis and its connection to seemingly unrelated diseases.
Researchers at Stanford University have directly observed plasmon resonances in individual metal particles measuring down to one nanometer in diameter. This discovery could lead to advancements in catalytic processes, cancer research and treatment, and quantum computing.
Researchers say forcing dying cancer cells to trigger an immune response could prevent cancer relapses and improve treatment benefits. The new strategy focuses on autophagy, a process that alerts the immune system to foreign invaders.
Researchers found that adding RNAi to standard TKI or antibody therapy can enhance the effect of therapy on NSCLC cell death and slow cell growth. The treatment may benefit patients with EGFR mutations who do not respond to TKI, or those whose cancer is driven by overactive EGFR production.
Researchers at Sanford-Burnham Medical Research Institute found that MLN4924-resistant cancer cells escape death due to a simple mutation in the NEDD8-activating enzyme. The team developed a method to predict how cancer patients will respond to this drug, providing a new path toward personalized medicine.
Scientists have successfully mapped tens of thousands of molecular signaling events involved in DNA damage repair, shedding light on how cells communicate when their DNA is broken. This research will help develop new drugs with fewer side effects and better protect healthy cells during cancer treatment.
Researchers sequenced DNA from cancer cells in patients with myelodysplastic syndromes who later developed leukemia, finding that the disease is an early form of cancer. The study suggests that targeted cancer drugs should be aimed at mutations that develop early in the disease.
Researchers at RIKEN successfully developed a new experimental technique for producing cells with specific functions by reconstructing transcriptional regulatory networks. This technique enables faster and more efficient production of functional cells for cancer therapy and other applications.
A recent study found that the protein Mer resides in the nucleus of leukemia cells, suggesting it may influence gene expression and contribute to cancer development. This discovery opens up new avenues for targeted treatments and potentially more accurate diagnoses.
A major study published in the Journal of Clinical Investigation has identified a method to stop bladder cancer from metastasizing to the lungs. The study found that adding the protein RhoGDI2 to tumors reduces versican production, blocking the ability of cancer cells to grow in the lungs.
Researchers found that telomeres send out a molecular SOS signal when cells take too long to divide, leading to the activation of DNA damage pathways and cell death. This discovery has implications for cancer chemotherapy, suggesting ways to make therapy more potent by combining mitotic inhibitors with other drugs.
Researchers at Weill Cornell Medical College have developed a new tool to image small-molecule metabolites in living cells, offering clues about how to treat disorders. The technology uses modified RNA called 'Spinach' to sense levels of target metabolites in real-time.
Cancer cells use an 'emergency brake' to protect themselves from chemotherapy drugs, which can be rendered inoperative by targeting a specific enzyme pathway. The study identifies PARP inhibition as a promising therapeutic approach to improve chemotherapy effectiveness.
Researchers found that a protein called FOXM1 protects cancer cells from chemotherapy and radiation-induced cell death. Combining standard drugs with proteasome inhibitors may improve treatment effectiveness.
A team from UNC Chapel Hill discovered how a long-studied protein complex influences cell movement and how cells respond to external cues. Cells without the protein complex exhibit altered structure and movement, affecting their ability to sense chemical cues and navigate surfaces.
A phase I clinical trial of patients with advanced pancreatic cancer showed promise with rigosertib, achieving stable disease in 11 of 19 patients for a median duration of 113 days. The drug targets PLK1 and PI3K signals that allow cancer cells to divide rapidly.
Researchers developed a novel technique to turn immune system killer T cells into more effective weapons by delivering DNA into instructor cells. The method proved effective in jumpstarting defective immune systems in immuno-compromised mice and human killer T cells, paving the way for potential cancer therapy.
Researchers at Harvard's Wyss Institute have developed a DNA nanorobot that can seek out specific cell targets and deliver molecular instructions to cause cancer cells to self-destruct. The technology uses modular components to mimic the body's immune system and has the potential to treat various diseases.
Researchers used Hi-C technology to generate a 3D model of a mouse genome and mapped chromosomal breaks to explore the impact of spatial proximity on reassembly. The study found that breaks near each other were more likely to be incorrectly attached to neighboring chromosomes.
Researchers at Yale University have identified a new regulator that controls p53's activity in sperm production, which could lead to breakthroughs in fertility treatments and cancer therapy. The study found that a molecule called Pumilo 1 plays a crucial role in this process.
Researchers have gained a better understanding of two key proteins that control cell division, which could lead to the development of new drugs to stop cancerous cells multiplying. This discovery could also help optimise personalised chemotherapy treatments and limit side effects associated with some chemotherapy drugs.
Scientists discovered that T cells can temporarily lose their ability to fight cancer when exposed to self-antigens, but return to normal function under certain conditions. Researchers hope to develop new cancer therapies by understanding and overcoming this tolerance mechanism.
Researchers discovered that nonsteroidal anti-inflammatory drugs (NSAIDS) inhibit tumor metastasis by reducing lymphatic vessel dilation and prostaglandin pathways. This mechanism provides a potential target for cancer treatment.
Researchers at the University of Washington have developed a new method to stimulate neurons in the brain using quantum dots. This technique allows for precise control over cell activity and could provide insights into disease processes and potential treatments for conditions like Parkinson's disease, Alzheimer's, and severe depression.
Monocytes are extremely sensitive to reactive oxygen species (ROS), while macrophages and dendritic cells derived from monocytes are resistant due to their defective DNA repair mechanisms. This sensitivity may play a role in regulating the immune response and preventing excessive ROS production.
Cell biologists have identified key steps in how small molecules alter a cell's skeletal shape and drive cell movement. By manipulating the cell membrane, researchers created ruffles that helped pull cells across surfaces, a process previously difficult to recreate.
Researchers have developed a novel technology platform that enables viewing of biological processes in dynamic, life-sustaining liquid environments. This innovation allows for high-resolution imaging of cancer cells and other macromolecules, providing new targets for drug therapy.
Researchers at the Translational Genomics Research Institute and University of Arizona have received a grant to study targeted cancer therapies for pancreatic cancer, which shows promise in reducing side effects. The center aims to develop novel antitumor agents that can extend the productive lives of patients with cancer.
Ziv Bar-Joseph, a Carnegie Mellon University professor, has received the Overton Prize for his outstanding contributions to computational biology. He has made significant breakthroughs in gene regulatory networks and their applications to cancer cells.
Researchers found grape seed extract to be effective in killing head and neck squamous cell carcinoma cells without harming healthy cells. The extract damages cancer cells' DNA and prevents repair pathways from functioning.
A study published in The Journal of Cell Biology reveals how DGK-alpha, a lipid-converting enzyme, enables invasive cancer cells to recycle integrins, providing better traction on fibronectin fibers. This process is essential for tumor progression and metastasis.
Research by Michael Goldberg and Phillip Sharp found that selectively inhibiting PKM2 can kill cancer cells by depleting energy sources. This approach has shown promise in regressing established tumors in mice, suggesting a potential strategy against various cancers.
Scientists found that caffeoylquinic acid derivatives from mate tea induce apoptosis in human colon cancer cells, reducing markers of inflammation. The study suggests mate tea has potential as an anti-cancer agent and may be beneficial for other diseases associated with inflammation.
Researchers have discovered that luteolin, a flavonoid found in fruit and vegetables, can inhibit the activity of cell signaling pathways important for colon cancer cell growth. This inhibition leads to reduced IGF-II secretion, decreased receptor expression, and ultimately, cell death.
Researchers discovered that the interaction between CD4 T cells and myeloid-derived suppressor cells (MDSC) can inhibit T-cell function, while CD8 T cells are not affected. The study suggests a potential mechanism for controlling dysregulated immune responses in cancer.
A faulty version of the RHBDF2 gene is responsible for tylosis with oesophageal cancer, a rare inherited condition. The study reveals that this gene malfunction leads to uncontrolled cell growth and division, causing cancer.
Researchers at UCSF have found that neutrophils use mechanical force to transmit tension across their membrane, restricting activity to the leading edge and enabling them to attack invaders. This discovery could lead to new therapies for conditions such as spinal cord injury and cancer.
A new imaging platform has been developed by Lawson researchers to study the moment when cancer cells turn deadly. The approach uses a shell-less chick embryo model implanted with human cancer cells, allowing scientists to modulate and monitor protein effects in real-time.
A study published in Leukemia identifies a molecular braking process that acute myeloid leukemia (AML) cells use to evade chemotherapy, allowing them to survive treatment. When this brake is removed, AML cells die, providing hope for improved survival rates for patients with the disease.
A new study has found that stomach cells from the cardia region may give rise to esophageal adenocarcinoma, a particularly lethal form of esophageal cancer. The research suggests a link between chronic inflammation and bile acid reflux in the development of this disease.
The study reveals that Raf-1 regulates cell adhesion, enabling cells to form new bonds and new blood vessels. The discovery may lead to cancer treatment approaches by targeting Raf-1 and disrupting tumor environments.
A new study has discovered that medications targeting the protein Mcl-1 can rapidly kill aggressive AML cells without harming non-cancerous blood cells. This finding provides hope for improved treatment options and potentially better patient outcomes for AML patients.
Researchers at UH Case Medical Center have discovered a novel treatment approach for cutaneous T-Cell lymphoma, which is a chronic and progressive disease affecting the skin. The new study finds that adding O6-benzylguanine to carmustine enhances topical chemotherapy efficacy, reducing toxicity and improving treatment outcomes.
MDC researchers found that both forms of therapy are highly effective against large tumors, but T-cell therapy also destroys the tumor blood vessel system, impeding nutrient supply and eradicating resistant tumor cells. This breakthrough may improve future clinical trials and cancer treatment
Scientists have discovered a new mechanism to identify Barrett's dysplasia cells using fluorescent probes and sugar molecules. This technology has the potential to monitor patients with pre-cancerous conditions and prevent the development of esophageal cancer.
Researchers created three-dimensional lab-made tissue models to study oral cancer, revealing the importance of epigenetic mechanisms in cancer development and progression. The findings support the need for more complex tissue-like systems in cancer drug screening, replacing conventional petri dish cultures.
A Stanford study found that a well-known protein complex controls DNA expression and prevents pancreatic cancer. The researchers discovered genetic changes in the protein complex were present in nearly a third of human pancreatic cancers, suggesting its role in tumor suppression.
Researchers at Brigham and Women's Hospital create drug delivery system that effectively targets prostate cancer cells, delivering high amounts of chemotherapeutic drugs. The innovative approach simplifies targeted nanoparticle development and broadens applications in cancer therapy.
Researchers identify PDHK enzyme as a key player in cancer cell metabolism, enabling targeted anti-cancer therapy. Inhibiting PDHK activity slows tumor growth and reduces glucose uptake by cancer cells.
Scientists at Albert Einstein College of Medicine have discovered a mechanism that controls the survival of messenger RNA in cells, which could lead to new treatments for cancer. The study found that mRNAs made from specific genes are born with molecular self-destruct timers that ultimately destroy them.
Researchers at the University of Southampton are working on enhanced MRI scans that can detect cancerous cells before they cause health problems. The new technology uses hyperpolarization to create incredibly strong NMR signals that last long enough for scans, allowing for earlier detection of abnormalities.
Researchers at Queen's University identified a new mechanism that could explain immune resistance in cancer cells, suggesting nitroglycerin may boost the body's natural immune response to cancer. The discovery sheds light on the role of hypoxia and ADAM10 enzyme production in cancer cell resistance.
Researchers at Moffitt Cancer Center have identified a chemical disrupter of the Rb-Raf-1 interaction, which may be vulnerable to targeting to prevent cancer cell proliferation and tumor growth. The study found that this disruption can limit metastasis in test mice, suggesting a potential new approach for combating metastatic disease.
Researchers at UWE Bristol and University of Bristol discovered that mutations in one specific cancer gene can control splicing balance, allowing a master switch to be turned on. This enables the growth of cancer cells and blood vessels, but new drugs targeting this process may block tumour growth.
A new drug, KPT-SINE, targets CRM1 protein to restore normal cell death pathways in cancer cells. This study provides proof-of-concept data for phase I clinical testing of KPT-SINE in patients with chronic lymphocytic leukemia (CLL) and related diseases.